ProQR Therapeutics Analysts Favor "Buy" Rating

ProQR Therapeutics (NASDAQ:PRQR) has recently received an average rating of "Buy" from five analysts monitoring its stock, according to reports. Among these analysts, four have provided a buy recommendation, while one analyst has assigned a strong buy rating to the biopharmaceutical company. The anticipated twelve-month price target set by brokers is $7.60.

A few brokerages have shared their insights regarding ProQR's stock. Chardan Capital reaffirmed a "buy" rating with a price target of $4.00 in a report dated December 12. Additionally, Raymond James upgraded ProQR from an "outperform" to a "strong-buy" and raised their target price from $6.00 to $14.00 on October 29. HC Wainwright also maintained a "buy" rating, setting a price target of $10.00 on December 12. On the same day, JMP Securities reiterated a "market outperform" rating with an $8.00 price target. However, StockNews.com downgraded ProQR from a "hold" rating to a "sell" rating in a report released on November 28.

Institutional Investors' Involvement

Recent activity from institutional investors shows potential confidence in ProQR Therapeutics. BNP Paribas Financial Markets increased its holdings in the company by 14.2% during the third quarter, owning 58,801 shares valued at $107,000 after acquiring an additional 7,300 shares. OneDigital Investment Advisors LLC also boosted its stake by 37.0%, bringing their total to 57,550 shares worth $105,000 after adding 15,550 shares. Furthermore, Privium Fund Management B.V. raised its holdings by 0.9%, now owning 5,632,388 shares valued at approximately $10,251,000 after purchasing an additional 51,663 shares in the last quarter. Currently, institutional owners account for 32.65% of the stock.

ProQR Therapeutics Stock Performance

As of Monday, PRQR's shares opened at $2.76. The 50-day moving average stands at $3.32, while the 200-day moving average is $2.48. The company has a market capitalization of $225.44 million, a price-to-earnings ratio of -8.63, and a low correlation beta of 0.30. ProQR's stock has fluctuated between a 1-year low of $1.61 and a 1-year high of $4.62.

Company Overview

ProQR Therapeutics N.V. is a biotechnology firm focused on discovering and developing innovative therapeutic medicines. Its product pipeline includes AX-0810, targeting cholestatic diseases via Na-taurocholate cotransporting polypeptide (NTCP), and AX-1412, intended for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

ProQR, Therapeutics, Stock